BioRestorative reports positive preliminary Phase 2 data for BRTX-100 in chronic lumbar disc disease

BioRestorative Therapies, Inc.

Preliminary 26-52 week blinded data from Phase 2 trial of BRTX-100 presented at ORS 2024 Annual Meeting.
Pain and function scales (VAS, ODI, RMDQ, FRI) show positive trend vs baseline at both follow-up points.
No notable safety signals observed in the ongoing study for chronic lumbar disc disease.
Company will host webcasted conference call today Feb 5 at 8:30am ET to discuss data and clinical update.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.